# A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

> **NCT05970640** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 64 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease
- Obesity

## Interventions

- **DRUG:** BI 3006337
- **DRUG:** Placebo matching BI 3006337

## Key facts

- **NCT ID:** NCT05970640
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-14
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-11-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970640, "A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05970640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*